Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
In 2021, the New England Journal of Medicine published the STEP 1 trial results: adults with obesity receiving semaglutide 2.4 mg/week lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group (Wilding et al., NEJM, 2021)
Welloop is not affiliated with or endorsed by the manufacturers of these medications
The rate of hospitalizations due to heart failure was lower with tirzepatide (3.3% vs 7.1%), as was intensification of oral diuretics (4.7% vs 5.7%)
For example, if you have one week with reduced appetite and then two weeks of feeling hungry again, it might mean your dose needs to be adjusted or that your body is adapting in ways your provider should be aware of
Wilding JP, Batterham RL, Davies M, et al
